AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01373853 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Phacoemulsification
Description: Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually
Study NCT00518505 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Symptom questionnaire
Description: This questionnaire will assess patient outcomes before and after surgery for gastroesophageal reflux disorder.
Study NCT03390361 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond Laser-assisted
Description: Laser cataract surgery will be performed in one eye
Study NCT03390361 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Manual Cataract Surgery
Description: Manual cataract surgery will be performed in contralateral eye
Study NCT02434952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin piperaquine (DHA PP)
Study NCT02434952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin piperaquine (DHA PP)
Study NCT02434952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Study NCT02434952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Study NCT02654379 — intervention group
Intervention type: BIOLOGICAL
Intervention: Rituximab
Description: Rituximab use in non-oncology indications
Study NCT02320721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine (HOE901 - U300)
Description: Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
Study NCT02320721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine (HOE901 - U100)
Description: Self-administered by SC injection in the evening using a pre-filled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
Study NCT02320721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy
Description: Non-insulin anti-diabetic drugs with the exception of thiazolidinediones.
Study NCT02320721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background therapy
Description: Non-insulin anti-diabetic drugs with the exception of thiazolidinediones.
Study NCT02514564 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise
Description: Patients included in the study will be enrolled in a cardiac rehabilitation program, in an independent manner of the study protocols.
Study NCT03929016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNDI-0690
Description: capsules of 10, 100 and 200 mg
Study NCT02398747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: 50mg continuous dosing, 125mg intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
Study NCT00641147 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00641147 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT02094079 — intervention group
Intervention type: OTHER
Intervention: biomedical outcomes
Description: Evaluation of abnormal blodtests (evaluating thyroid function) from predefined control program
Study NCT04902950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The Tranexamic acid soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient.
Study NCT04902950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The saline soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient.
Study NCT04695587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECHO
Description: ECHO in subacute phase and 12 months after the acute episode
Study NCT04695587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 24hour ECG
Description: 24hour ECG in subacute phase and 12 months after the acute episode
Study NCT04695587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CMR
Description: CMR in 12 months after the acute episode
Study NCT02360605 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: automated telephone reminder
Description: The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT. ATR will remind the patient of the importance of completing and returning the FIT results and encourage screening completion. There will also be an option where the patient can request another FIT kit be mailed to them, one to hear information on common problems with FIT completion or how to call the clinic if they have questions. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up ATR calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
Study NCT02360605 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: prevention coordinator
Description: The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT by a prevention coordinator (PC). PC will call to encourage completion and ascertain any barriers to completion. The PCs will use Health Literacy and motivational interviewing techniques described in the training section to enhance understanding and confidence and reduce ambivalence to completing and returning the FIT. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up PC calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
Study NCT02360605 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health literacy appropriate education and demonstration
Description: The Research Assistant (RA) will employ health literacy communication principles in providing a CRC recommendation and brief screening information using the CRC pamphlet and a FIT kit with simplified instructions and accompanying self-addressed, stamped envelope. A scripted message and illustrations will model what the patient needs to do to complete the FIT. The RA will appropriately demonstrate, using the kit, and will suggest patients show the pamphlet and FIT kit to their provider that day and talk to them about screening. Annual screening will be further emphasized at enrollment by giving patients an empowering message about the benefits of completing a FIT annually and telling them they will be mailed a reminder letter and FIT kit and receive outreach phone calls in 12 and 24 months for the next two years as well as a post survey and satisfaction interview over the phone at 6 months.
Study NCT00955383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK2190915
Description: GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
Study NCT02365532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-6615
Description: GS-6615 tablets administered orally
Study NCT03929016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of DNDI-0690
Description: capsules of matching placebo
Study NCT02365532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GS-6615
Description: Placebo to match GS-6615 tablets administered orally
Study NCT02365532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match GS-6615
Description: Placebo to match GS-6615 tablets administered orally
Study NCT02365532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match dofetilide
Description: Placebo to match dofetilide capsules administered orally
Study NCT02365532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match dofetilide
Description: Placebo to match dofetilide capsules administered orally
Study NCT02365532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dofetilide
Description: Dofetilide 500 μg capsules administered orally according to the current prescribing information
Study NCT02365532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dofetilide
Description: Dofetilide 500 μg capsules administered orally according to the current prescribing information
Study NCT04397055 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cottonseed Oil
Description: Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Cottonseed Oil
Study NCT04397055 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive Oil
Description: Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Olive Oil
Study NCT00955383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT04655586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rNAPc2
Description: two dose levels of rNAPc2
Study NCT04655586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: standard of care heparin per institution (therapeutic or prophylactic regimen)
Study NCT01011062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia
Description: Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp
Study NCT01011062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Acute administration of losartan 200mg total prior to clamp
Study NCT01011062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Infusion of Saline as a volume control intervention
Study NCT04469530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus is given at a dose of 2 mg/m2 once daily. The amber oral dose syringe should be used to withdraw the prescribed amount of sirolimus oral solution from the bottle. The solution can be drunk or administered at once to assure delivery of all of the medication. It is safe for administration through a nasogastric or G-tube. For tablets, the tablet should not be crushed, split, or otherwise altered. As with the liquid dosing form, the tablets should be given within two hours each day and should be at consistent intervals with regard to meals.
Study NCT04469530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A synthetic antineoplastic drug chemically related to the nitrogen mustards. The drug is administered orally daily, in the formulation appropriate for age.~The solution should be diluted in 20-30 ml of appropriate liquid before administration through nasogastric (NG) tube or gastrostomy (G) tube, with adequate flushing after administration to prevent obstruction of the feeding tube.
Study NCT00924638 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reveal® XT Insertable Cardiac Monitor
Description: The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.
Study NCT00757419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: capsules, oral, single or twice daily dose
Study NCT00757419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To match dosing of AZD3355
Study NCT02988258 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CMV-TCR transduced donor-derived T cells
Description: Dose escalation
Study NCT01269658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin ophthalmic solution, 1%
Description: 1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
Study NCT01269658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
Study NCT02928744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD
Description: Plethysmography
Study NCT02928744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD
Description: Forced oscillations
Study NCT02047305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: Patients with a histopathological diagnosis of moderate-grade intra-epithelial neoplasia (MGIN), high-grade intra-epithelial neoplasia (HGIN) and/or early flat-type SCCA of the esophagus, are treated with radiofrequency ablation, with repeat endoscopy and follow-up treatment at 3 month intervals.
Study NCT03392051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 681257
Description: Xmg dose administered as a subcutaneous injection
Study NCT03392051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 75mg tablet administered orally
Study NCT05768334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lubiprostone 24Mcg Oral twice daily
Description: The patients will be randomized (closed envelopes) into one of two groups:~1. Fifty patients will receive lubiprostone 24 mcg (microgram) twice daily.~2. Fifty patients will receive placebo twice daily (control group). All patients will be followed for 48 weeks.
Study NCT05768334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone 24Mcg Oral twice daily
Description: The patients will be randomized (closed envelopes) into one of two groups:~1. Fifty patients will receive lubiprostone 24 mcg (microgram) twice daily.~2. Fifty patients will receive placebo twice daily (control group). All patients will be followed for 48 weeks.
Study NCT04658225 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 0.12% chlorhexidine
Description: the patients were randomly allocated into two groups of 15 individuals to rinse with antimicrobials twice a day for a period of four weeks. Group A, received 0.12% chlorhexidine antimicrobian in a vial previously identified as solution 1 and group B, received saline solution identified as solution 2.
Study NCT04658225 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 0.12% chlorhexidine
Description: the patients were randomly allocated into two groups of 15 individuals to rinse with antimicrobials twice a day for a period of four weeks. Group A, received 0.12% chlorhexidine antimicrobian in a vial previously identified as solution 1 and group B, received saline solution identified as solution 2.
Study NCT01291095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CISPLATIN
Description: IN CRT ARM:RADIATION ONE FRACTION PER DAY, ON FIVE CONSECUTIVE DAYS FROM MONDAY TO FRIDAY ALONG WITH INTRAVENOUS CISPLATIN 40mg/m2 WEEKLY FOR SEVEN DOSES.~IN AFRT ARM: PATIENTS WILL NOT RECEIVE ANY CHEMOTHERAPY WITH CISPLATIN
Study NCT01291095 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EXTERNAL BEAM RADIOTHERAPY
Description: Patients assigned to CRT arm will be given radiation one fraction per day, on five consecutive days from Monday to Friday along with intravenous cisplatin 40 mg/m2 weekly for seven doses (a minimum of 5weekly chemotherapy). Patients assigned to AFRT arm will undergo radiation similarly one fraction per day and then the sixth fraction will be given on another day (Saturday) or as an extra fraction on one of the first five days, but always allowing at least a 6-hour interval between fractions on same day. If any unintended interruption of the treatment occurs, this missing treatment will be given as soon as possible, preferably within a week, but not allowing more than 14 Gy to be given during any 7-day period.
Study NCT01291095 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: EXTERNAL BEAM RADIOTHERAPY
Description: Patients assigned to CRT arm will be given radiation one fraction per day, on five consecutive days from Monday to Friday along with intravenous cisplatin 40 mg/m2 weekly for seven doses (a minimum of 5weekly chemotherapy). Patients assigned to AFRT arm will undergo radiation similarly one fraction per day and then the sixth fraction will be given on another day (Saturday) or as an extra fraction on one of the first five days, but always allowing at least a 6-hour interval between fractions on same day. If any unintended interruption of the treatment occurs, this missing treatment will be given as soon as possible, preferably within a week, but not allowing more than 14 Gy to be given during any 7-day period.
Study NCT02966782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Tablet
Study NCT02966782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Powder for injection, subcutaneously or intravenous
Study NCT02881541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced support
Study NCT02881541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual care
Study NCT02075645 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Team training course
Description: A 1-day simulation-based team-training course. There will be 4 simulated resuscitation events. Simulation #1 will be the pre-course team performance and simulation #4 will be the post-course performance.
Study NCT04178122 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Result disclosure
Description: Disclosure of clinically confirmed, medically actionable genetic testing results and post-test genetic counseling session.
Study NCT03822130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arterial catheter infusion chemotherapy
Description: Arterial catheter infusion chemotherapy
Study NCT03822130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Arterial catheter infusion Sodium Bicarbonate
Study NCT03822130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Systemic Chemotherapy
Description: Systemic Chemotherapy
Study NCT03822130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Chemotherapy
Description: Oral Chemotherapy
Study NCT03822130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Chemotherapy
Description: Oral Chemotherapy
Study NCT03366792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artemis™ software system
Description: Computerized targeting of mpMRI lesions. The computerized co-registration will then be performed by software within the Artemis™ system and will fuse the MR imaging with real-time ultrasound imaging.
Study NCT04469530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: A semisynthetic derivative of podophyllotoxin which functions as mitotic inhibitor but does not interfere with microtubular assembly. The drug is administered orally daily, in the formulation appropriate for age.
Study NCT04469530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: The drug is administered orally daily, in the formulation appropriate for age.The solution is safe for administration through a nasogastric or G-tube.
Study NCT03918031 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PFI for Smoking & Distress Tolerance
Description: Personalized Feedback Intervention for smoking and distress tolerance.
Study NCT03918031 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PFI for Smoking Only
Description: Personalized Feedback Intervention for smoking only (no distress tolerance component)
Study NCT03209453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: family work shop
Description: Children with developmental delays, under regular rehabilitation programs, participate 6 sessions of family work shop The family work shop had 6 families in one course, 2 hours per week, for a total of 6 weeks.